
Copyright © Midlands and Lancashire Commissioning Support Unit

Medicines Safety Assurance Tool

December 2022






MHRA consultation with healthcare professionals (HCPs) on their safety communications 01 December 2022 MHRA is reviewing its approach to engagement on safety of medicines & medical devices. Its consultation is enabling HCPs across UK to have their say on how they wish to receive vital safety information, how they'd like to be engaged & to feedback on Yellow Card system.	Proposed action ☑ Newsletter ☐ Practice audit/search Action taken	☐ Optimise Rx/ScriptSwit☐ Other (please specify)	
	Status	Action due date	Date completed
PRAC recommends withdrawal of pholcodine medicines from EU market 05 December 2022	Proposed action ☑ Newsletter ☐ Practice audit/search	☐ Optimise Rx/ScriptSwit☐ Other (please specify)	
Data found use of pholcodine within 12 months of general anaesthesia is a risk factor for developing an anaphylactic reaction to neuromuscular blocking agents. As it was not possible to identify measures to minimise the risk, the market authorisation is being withdrawn in the EU.			
	Action taken		
	Status	Action due date	Date completed

Copyright © Midlands and Lancashire Commissioning Support Unit

Medicines Safety Assurance Tool

December 2022





Valproate: reminder of current Pregnancy Prevention Programme requirements; information on new safety measures to be introduced in the coming months 12 December 2022 In view of data showing ongoing exposure to valproate in pregnancy, this alert reminds HCPs of the risks in pregnancy, current Pregnancy Prevention Programme requirements and the new safety measures being put into place in the coming months following advice from CHM.	Proposed action ☑ Newsletter ☐ Practice audit/search	☐ Optimise Rx/ScriptSwit☐ Other (please specify)	xch
	Action taken		
	Status	Action due date	Date completed
Assessing the impact of renal impairment on medicines safety in adults 19 December 2022	Proposed action ☑ Newsletter ☐ Practice audit/search	□ Optimise Rx/ScriptSwitch□ Other (please specify)	
This article, part of a series on renal impairment and supported by information resources, provides advice on the considerations needed to assess renal function and ensure the safe use of medicines in the context of preserving kidney function.			
	Action taken		
	Status	Action due date	Date completed
	Status	Action due date	Date completed

Copyright © Midlands and Lancashire Commissioning Support Unit

Medicines Safety Assurance Tool

December 2022

To request this safety tool, or for more information about this tool, to make a comment, or share a safety issue please contact micromation about this tool, to make a comment, or share a safety issue please contact micromation about this tool, to make a comment, or share a safety issue please contact.



Summary of Product Characteristics updates

Lipitor (atorvastatin) 10 and 20 mg chewable tablets

Immune-mediated necrotizing myopathy has been added to SPC as an adverse drug reaction and ledipasvir/sofosbuvir added to list of antivirals for treatment of hepatitis C that may increase risk of myopathy with concomitant use with atorvastatin.

Lyrica (pregabalin) hard capsules- all strenghts

Toxic epidermal necrolysis has been added to SPC as a rare adverse effect.

Phenergan (promethazine)- all presentations

Updated to warn phenothiazine derivatives, of which promethazine is one, may potentiate QT prolongation (QTP), increasing risk of serious ventricular arrhythmias of torsade de pointes type. Special caution required when used concurrently with drugs known to cause QTP.

Zoton (lansoprazole) Fas Tab 15mg and 30mg

SPC updated with information warning about acute tubulointerstitial nephritis, which has been observed in patients taking lansoprazole and may occur at any point during treatment, and can progress to renal failure.

Proposed action			
☑ Newsletter	☐ Optimise Rx/Scrip	otSwitch	
$\ \square$ Practice audit/search	☐ Other (please spe	ecify)	
Action taken			
Status	Action due date	Date com	pleted

Copyright © Midlands and Lancashire Commissioning Support Unit

Medicines Safety Assurance Tool

December 2022

To request this safety tool, or for more information about this tool, to make a comment, or share a safety issue please contact micsu.medicines-safety@nhs.net



About this document

MLCSU collates and shares the latest current awareness and evidence-based medicines information from NICE and UKMi relating to medicines safety each month

© NICE 2023. All rights reserved. Subject to Notice of rights.

NICE guidance is prepared for the National Health Service in England. All NICE guidance is subject to regular review and may be updated or withdrawn. NICE accepts no responsibility for the use of its content in this product/publication